Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X:
“EORTC 1333 / PEACE-3 final OS.
Enzalutamide + Radium-223 improved OS
HR 0.76. rPFS also better. Toxicity higher but manageable. Bone protection mandatory.
But here is the real question: Most mCRPC patients already received an ARPI earlier.
So where does this fit today? Likely in a selected group:
- Bone-only disease.
- Good performance status.
- Limited prior ARPI exposure or long ARPI response.
- No visceral metastases.
Sequencing now matters more than ever.”
Other articles featuring Yüksel Ürün on OncoDaily.
